CN106666747A - Water-soluble fatty acid component nano-particles for infants - Google Patents
Water-soluble fatty acid component nano-particles for infants Download PDFInfo
- Publication number
- CN106666747A CN106666747A CN201611234080.2A CN201611234080A CN106666747A CN 106666747 A CN106666747 A CN 106666747A CN 201611234080 A CN201611234080 A CN 201611234080A CN 106666747 A CN106666747 A CN 106666747A
- Authority
- CN
- China
- Prior art keywords
- fatty acid
- acid
- content
- component nano
- acid component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 42
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 42
- 239000000194 fatty acid Substances 0.000 title claims abstract description 42
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 42
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 24
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 35
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 16
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 13
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 8
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 241000907999 Mortierella alpina Species 0.000 claims abstract description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims abstract description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000839 emulsion Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 238000000265 homogenisation Methods 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 10
- 238000001694 spray drying Methods 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 238000010008 shearing Methods 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 239000008346 aqueous phase Substances 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 241000195493 Cryptophyta Species 0.000 claims description 5
- 235000019197 fats Nutrition 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- -1 sucrose ester Chemical class 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- 235000013826 starch sodium octenyl succinate Nutrition 0.000 claims description 3
- 239000001334 starch sodium octenyl succinate Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims description 2
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 2
- 229960005055 sodium ascorbate Drugs 0.000 claims description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 2
- 229940080237 sodium caseinate Drugs 0.000 claims description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 235000009392 Vitis Nutrition 0.000 claims 1
- 241000219095 Vitis Species 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000021588 free fatty acids Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 7
- 239000003094 microcapsule Substances 0.000 description 6
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 6
- 235000001727 glucose Nutrition 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 150000000998 L-ascorbyl palmitates Chemical class 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- YEBDWAHEIMUJQT-ZLCLUPBPSA-N (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YEBDWAHEIMUJQT-ZLCLUPBPSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Natural products CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229940061584 phosphoramidic acid Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to water-soluble fatty acid component nano-particles for infants and a preparation method of the water-soluble fatty acid component nano-particles, and belongs to the field of food and drugs. The water-soluble fatty acid component nano-particles are prepared from components by mass as follows: 10%-30% of fatty acid, 10%-85% of a wall material, 0.005%-5.5% of an antioxidant and 0.5%-15% of an emulsifier, wherein the fatty acid is a mixture of alpha-linolenic acid, DHA (docosahexaenoic acid) and ETA (eicosatetraenoic acid) which exit in forms of free fatty acid, glyceride or ethyl ester; in terms of purity requirement, the content of alpha-linolenic acid is higher than or equal to 75wt%, DHA comes from algal oil extract, the content of DHA is higher than or equal to 45wt%, ETA comes from mortierella alpine, and the content of ETA is higher than or equal to 45wt%. According to the nanoparticles, the three fatty acids are uniformly mixed in a dietary proportion, then a product is encapsulated to be prevented from being contacted with oxygen, and the nanoparticles can be mixed with food for use.
Description
Technical field
The present invention relates to a kind of infant water solublity fatty acid component nano-particle and preparation method thereof, belongs to food and medicine
Field.
Background technology
Alpha-linolenic acid itself can only can not be synthesized by food supply, human body, be referred to as essential fatty acid.Suitable
Under the conditions of by desaturation or c-terminuses can be extended synthesize various long-chain unsaturated fatty acids, such as DHA, EPA and AA.To baby god
The formation of Jing myelins and the development of brain have an extremely important effect, and with maintaining the integrity of cell membrane, safeguard the screen of skin
Barrier function, and be conducive to the development of baby's vision.Due to the enzymatic activity that baby itself synthesizes these fatty acids it is relatively low, it is impossible to
Meet the growth promoter needs of baby, needs are supplemented from food.So, give baby food must assure that fatty acid with
And the value volume and range of product of some long-chain polyunsaturated fatty acids, ensure the normal growth development of baby.
Arachidonic acid (Arachidonic acid), systematic naming method is 5,8,11,14-all-cis-two ten carbon four
Olefin(e) acid, also known as 5,8,11,14-arachidic acid is a kind of important polyunsaturated fatty acid of human body of n-6 series, referred to as
AA.It is mainly distributed in phospholipid form in the organ of mammal, muscle and blood, wherein in brain and nervous tissue,
The content of AA typically constitutes from the 40%~50% of single PUFAs, and in teleneuron 70% is even as high as.AA is in retina
It is the most abundant long-chain polyunsaturated fatty acid of content, fetus and infant central nervous system and retina neural development is had
Special role, is the essential nutrients of mankind's early development（Wang Haitang. arachidonic health-care effect ［ J ］. food industry section
Skill, 2003,24 (5):97-98.）Outside this, AA also has to be improved memory and vision, adjusts blood fat and blood glucose, prevents painstaking effort
Pipe disease, auxiliary suppress the effects such as tumor, prevention canceration.
DHA is one of main composition of the abundant PUFAs of cellular phospholipid layer in brain nervous cell, accounts for human body cerebral tissue
The 10% of fat.For the formation of brain cell membrane plays an important role.Additionally, DHA is in phosphoramidic acid, acetylcholine and silk ammonia
Also there is substantial amounts of distribution in sour phospholipid glyceride, he is the indispensable material base of mankind's central nervous tissue, to nerveous system
The development of system plays the role of important.For fetus and infant, two kinds of main fatty acid DHA and AA in brain, to fetus
Brain is formed and the development of infant is most important.The baby of food breast milk is higher than the youngster of artificial breast nursing to IQ when 7-8 year
Child, this is the development that can promote intelligence due to containing DHA in breast milk.
DHA and AA are respectively the polyunsaturated fatty acid of ω -3 and ω -6 series, in threpsology and biologically have
Significance, unsaturated fatty acid is the important nutritional labeling of brain and cranial nerve, can lift infant intelligence developmental index, is lifted
Visual acuity.The foundation of South West USA retina shows important shadows of the AA to infant intelligent development to AA function tests itself
Ring, also show AA and DHA and arrange in pairs or groups in proportion more reasonability.
Although mammal can will obtain food ALA and change into EPA and DHA from food, this transformed in human body
Journey is slower, and efficiency is again very low, and ALA effectively can not be converted into DHA by infant.Therefore, directly DHA is absorbed more from meals
The level in brain can be effectively improved, is optimal directly to absorb DHA.
Therefore, in infant feeding, the great attention of people should be caused to the supplement of PUFA.U.S.'s Mertek bioscience
Company produces the special dietary component oil of a kind of entitled " Formulaid ", for baby with DHA and AA as main functional component
Formula food or nutrition enhancer.But because the chemical property of unsaturated double-bond in polyunsaturated fatty acid is very active, expose
Easily it is oxidized in atmosphere and decomposes and cause and become sour, oxidation reaction is accelerated when being heated, aoxidizes the volatilization or non-volatile degraded for generating
Thing is serious to health infringement.
The content of the invention
The technical problem to be solved is to provide a kind of infant water solublity fatty acid component nano-particle.
Percentage ratio hereinafter, is all mass percent if be not indicated otherwise.
The water solublity fatty acid component granule of the present invention is by fatty acid, wall material, antioxidant, emulsifying agent composition, by matter
The content of gauge, wherein fatty acid is 10-30%；Wall material content is 10-85%；Oxidation preventive content is 0.005-5.5%；Emulsifying
Agent content is 0.5-15%, and the fatty acid is alpha-linolenic acid（ALA）, docosahexenoic acid（DHA）, eicosatetraenoic acid
(AA) three kinds of mixture；The alpha-linolenic acid（ALA）, docosahexenoic acid（DHA）, eicosatetraenoic acid (AA) is with free
In the form of fatty acid, glyceride or ethyl ester；
It is as follows to their purity requirement：Alpha-linolenic acid（ALA）Content >=75%, docosahexenoic acid（DHA）From algae oil
Extract, content >=45%, eicosatetraenoic acid (AA) derives from Mortierella alpina, content >=45%.
In described fatty acid component nano-particle, the mass ratio of each fatty acid is alpha-linolenic acid（ALA）：22 carbon six
Olefin(e) acid（DHA）：Eicosatetraenoic acid (AA)=（1-8.5）：（1-2）：（1-7）.
The wall material selected from starch sodium octenyl succinate, arabic gum, sodium caseinate, lactalbumin, soybean protein,
One or more in gelatin, maltodextrin, glucose syrup, glucose, Lactose, sucrose；The emulsifying agent is selected from monostearate
One kind in glyceride, sucrose ester or two kinds；The antioxidant is selected from Vitamin E, ascorbic acid, sodium ascorbate, anti-bad
One or more in hematic acid cetylate.
Particle diameter≤650 nm of described fatty acid component nano-particle；Embedding rate >=95%, there is good water solublity.
A kind of preparation method of infant water solublity fatty acid component nano-particle, comprises the following steps that：
1) wall material, antioxidant, emulsifying agent are mixed in 40 DEG C of -90 DEG C of water and are stirred to being uniformly dispersed, aqueous phase solution is obtained；
2) three kinds of fatty acids and antioxidant are stirred to being uniformly dispersed, oil phase is obtained in 30 DEG C of -90 DEG C of stirring 5-10min of temperature
Solution；
3) by step 2) gained oil-phase solution adds step 1) obtain mixture in gained aqueous phase solution, high-speed shearing machine with
The speed of 3000r/min-6000r/min is sheared, and shear time is 5-20 minutes, and colostric fluid is obtained；
4) by step 3）The colostric fluid for obtaining carries out three sub-high pressure homogenizing, and first time homogenization pressure is 10-40MPa, and second
Matter pressure is 40-70MPa；Third time homogenization pressure is 50-100MPa, obtains emulsion；
5) by step 4）Emulsion carry out 2-5min, Jing Centrafugal spray drying towers are sprayed after 80-98 DEG C of pasteurize
Powdery fat acid component nano-particle is obtained after drying.
The inlet temperature of the spray drying is 140-200 DEG C, and leaving air temp is 75-100 DEG C.
The nano-particle of the present invention is encapsulated after its three kinds of fatty acids are mixed according to meals ratio to it, in case
Only contact with oxygen, and can be used in mixed way with food.
Specific embodiment
Embodiment one
1) 2.75kg starch sodium octenyl succinate is weighed, 4.10kg glucose syrups, 2.32kg Lactose, 0.93kg monoglycerides,
0.30kg sodium ascorbates are added after mixing and stirred in 45 DEG C of water to being uniformly dispersed, and aqueous phase solution is obtained.
2) 1.10kg80% alpha-linolenic acids, algae oil DHA of 0.28kg purity 45%, the arachidonic of 0.83kg purity 50% are weighed
Acid glyceride and 0.01kg Vitamin E stir 10min to being uniformly dispersed at 35 DEG C, obtain oil-phase solution.
3) by step 2）The oil phase of gained is slowly added to 1）In obtain mixed solution, with high-speed shearing machine in 5000r/min,
Colostric fluid is obtained after shearing 10min.
4) by step 3）The colostric fluid for obtaining carries out three sub-high pressure homogenizing, and first time homogenization pressure is 15MPa, and second
Matter pressure is 30MPa；Third time homogenization pressure is 45MPa, obtains emulsion.
5) by step 4）The emulsion for obtaining Jing Centrafugal spray drying towers after 3min, 85 DEG C of pasteurize are sprayed
Mist is obtained fatty acid microcapsule after being dried, the inlet temperature of the spray drying is 175 DEG C, and leaving air temp is 80 DEG C；Microcapsule
Oil content 17.5%, it is 97.4% to survey envelop rate, and epigranular, granularity is 321-467nm.
Embodiment two
1) 2.79kg arabic gums are weighed, 1.62kg glucoses, 1.62kg sucrose, 0.35kg monoglycerides, 0.45 sucrose ester,
0.19kg ascorbic acid is added after mixing and stirred in 75 DEG C of water to being uniformly dispersed, and aqueous phase solution is obtained.
2) 1.10kg75% alpha-linolenic acid glyceride is weighed, algae oil DHA of 0.44kg purity 50%, 0.66kg purity 65%
Arachidonic acid glyceride and 0.02kg ascorbyl palmitates stir 7min to being uniformly dispersed at 48 DEG C, obtain oil phase molten
Liquid.
3) by step 2）The oil phase of gained is slowly added to 1）In obtain mixed solution, with high-speed shearing machine in 4500r/min,
Colostric fluid is obtained after shearing 18min.
4) by step 3）The colostric fluid for obtaining carries out three sub-high pressure homogenizing, and first time homogenization pressure is 20MPa, and second
Matter pressure is 30MPa；Third time homogenization pressure is 50MPa, obtains emulsion.
5) by step 4）The emulsion for obtaining Jing Centrafugal spray drying towers after 3min, 80 DEG C of pasteurize are sprayed
Mist is obtained fatty acid microcapsule after being dried, the inlet temperature of the spray drying is 190 DEG C, and leaving air temp is 85 DEG C；Microcapsule
Oil content 23.6%, it is 98.7% to survey envelop rate, and epigranular, granularity is 294-381nm.
Embodiment three
1) 2.28kg sodium caseinates are weighed, 3.83kg soybean protein isolates, 2.81kg glucose syrups, 0.90kg sucrose ester,
0.64kg sodium ascorbates are added after mixing and stirred in 55 DEG C of water to being uniformly dispersed, and aqueous phase solution is obtained.
2) 2.52kg80% Alpha-ethyl linolenates, algae oil DHA of 0.43kg purity 45%, the flower of 0.86kg purity 50% are weighed
Raw tetraenoic acid and 0.02kg Vitamin E and 0.01kg ascorbyl palmitates stir 8min to being uniformly dispersed at 55 DEG C, obtain
To oil-phase solution.
3) by step 2）The oil phase of gained is slowly added to 1）In obtain mixed solution, with high-speed shearing machine in 5000r/min,
Colostric fluid is obtained after shearing 20min.
4) by step 3）The colostric fluid for obtaining carries out three sub-high pressure homogenizing, and first time homogenization pressure is 20MPa, and second
Matter pressure is 40MPa；Third time homogenization pressure is 80MPa, obtains emulsion.
5) by step 4）The emulsion for obtaining Jing Centrafugal spray drying towers after 3min, 85 DEG C of pasteurize are sprayed
Mist is obtained fatty acid microcapsule after being dried, the inlet temperature of the spray drying is 185 DEG C, and leaving air temp is 70 DEG C；Microcapsule
Oil content 26.8%, it is 96.9% to survey envelop rate, and epigranular, granularity is 182-298nm.
Claims (9)
1. a kind of infant water solublity fatty acid component nano-particle, by fatty acid, wall material, antioxidant, emulsifying agent composition, presses
The content of quality meter, wherein fatty acid is 10-30%；Wall material content is 10-85%；Oxidation preventive content is 0.005-5.5%；Breast
Agent content is 0.5-15%, and the fatty acid is the mixture of alpha-linolenic acid, docosahexenoic acid and eicosatetraenoic acid；
The alpha-linolenic acid, docosahexenoic acid, eicosatetraenoic acid are in the form of free fatty, glyceride or ethyl ester；
Purity requirement to fatty acid is as follows：Alpha-linolenic acid content >=75wt%, docosahexaenoic acid source is extracted in algae oil
Thing, content >=45wt%, eicosatetraenoic acid derives from Mortierella alpina, content >=45wt%.
2. infant water solublity fatty acid component nano-particle according to claim 1, it is characterised in that each fatty acid
Mass ratio is alpha-linolenic acid：Docosahexenoic acid：Eicosatetraenoic acid=（1-8.5）：（1-2）：（1-7）.
3. infant water solublity fatty acid component nano-particle according to claim 1, it is characterised in that the wall material choosing
From starch sodium octenyl succinate, arabic gum, sodium caseinate, lactalbumin, soybean protein, gelatin, maltodextrin, Fructus Vitis viniferae
One or more in syrup, glucose, Lactose, sucrose.
4. infant water solublity fatty acid component nano-particle according to claim 1, it is characterised in that the emulsifying agent
One kind in glyceryl monostearate, sucrose ester or two kinds.
5. infant water solublity fatty acid component nano-particle according to claim 1, it is characterised in that the antioxidation
One or more of agent in Vitamin E, ascorbic acid, sodium ascorbate, ascorbyl palmitate.
6. infant water solublity fatty acid component nano-particle according to claim 1, it is characterised in that described fat
Particle diameter≤650 nm of sour component nano-particle；Embedding rate >=95%.
7. the preparation method of the infant water solublity fatty acid component nano-particle described in claim 1, including following technique is walked
Suddenly：
1）Wall material, antioxidant, emulsifying agent are mixed in 40 DEG C of -90 DEG C of water and are stirred to being uniformly dispersed, aqueous phase solution is obtained；
2）Three kinds of fatty acids and antioxidant are stirred to being uniformly dispersed, oil phase is obtained in 30 DEG C of -90 DEG C of stirring 5-10min of temperature
Solution；
3）By step 2) gained oil-phase solution adds step 1) obtain mixture in gained aqueous phase solution, high-speed shearing machine with
The speed of 3000r/min-6000r/min is sheared, and shear time is 5-20 minutes, and colostric fluid is obtained；
4）By step 3）The colostric fluid for obtaining carries out three sub-high pressure homogenizing, and first time homogenization pressure is 10-40MPa, and second
Matter pressure is 40-70MPa；Third time homogenization pressure is 50-100MPa, obtains emulsion；
5）By step 4）Emulsion carry out 2-5min, Jing Centrafugal spray drying towers are sprayed after 80-98 DEG C of pasteurize
Powdery fat acid component nano-particle is obtained after drying.
8. preparation method according to claim 7, it is characterised in that the inlet temperature of the spray drying is 140-200
DEG C, leaving air temp is 75-100 DEG C.
9. the infant water solublity fatty acid nano-particle described in any one of claim 1-7 is used as fatty acid component and infant
The purposes of food additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611234080.2A CN106666747A (en) | 2016-12-28 | 2016-12-28 | Water-soluble fatty acid component nano-particles for infants |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611234080.2A CN106666747A (en) | 2016-12-28 | 2016-12-28 | Water-soluble fatty acid component nano-particles for infants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106666747A true CN106666747A (en) | 2017-05-17 |
Family
ID=58872793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611234080.2A Pending CN106666747A (en) | 2016-12-28 | 2016-12-28 | Water-soluble fatty acid component nano-particles for infants |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106666747A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110692962A (en) * | 2019-10-12 | 2020-01-17 | 山东省食品发酵工业研究设计院 | Preparation method of winter jujube composite powder containing DHA algae oil nanoparticles |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1145222A (en) * | 1995-09-15 | 1997-03-19 | 哈尔滨高明高新技术发展有限公司 | Method for prepn. of polyalkene fatty acid powder |
| CN101125133A (en) * | 2007-09-27 | 2008-02-20 | 武汉麦可得生物技术有限公司 | Unsaturated fatty acid microcapsule preparing technology and application |
| CN101259101A (en) * | 2008-04-17 | 2008-09-10 | 湖北福星生物科技有限公司 | Micrometre level arachidonic acid/docosahexaenoic acid emulsion and preparation thereof |
| CN101669920A (en) * | 2008-09-10 | 2010-03-17 | 阜宁怀仁生物有限公司 | Strong anti-oxidation DHA microcapsule and preparation method thereof |
| CN102228257A (en) * | 2011-06-27 | 2011-11-02 | 湖北福星生物科技有限公司 | Algal oil DHA (Docosahexaenoic Acid) microcapsule and preparation method thereof |
| CN102771781A (en) * | 2011-05-07 | 2012-11-14 | 于文利 | Preparation method of novel nano DNA nutrition powder |
| CN103549442A (en) * | 2013-11-01 | 2014-02-05 | 厦门汇盛生物有限公司 | High-oil-load DHA (docosahexaenoic acid) algae oil microcapsule powder and preparation technique thereof |
| CN104719510A (en) * | 2015-03-20 | 2015-06-24 | 湖南洋膳科技有限公司 | Pregnant woman and infant nutritional tea oil containing DHA and AA |
| CN105661545A (en) * | 2016-01-28 | 2016-06-15 | 武汉欧米嘉生物医药有限公司 | Alpha-linolenic acid microcapsule capable of being directly used for cooking and preparation method of alpha-linolenic acid microcapsule |
-
2016
- 2016-12-28 CN CN201611234080.2A patent/CN106666747A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1145222A (en) * | 1995-09-15 | 1997-03-19 | 哈尔滨高明高新技术发展有限公司 | Method for prepn. of polyalkene fatty acid powder |
| CN101125133A (en) * | 2007-09-27 | 2008-02-20 | 武汉麦可得生物技术有限公司 | Unsaturated fatty acid microcapsule preparing technology and application |
| CN101259101A (en) * | 2008-04-17 | 2008-09-10 | 湖北福星生物科技有限公司 | Micrometre level arachidonic acid/docosahexaenoic acid emulsion and preparation thereof |
| CN101669920A (en) * | 2008-09-10 | 2010-03-17 | 阜宁怀仁生物有限公司 | Strong anti-oxidation DHA microcapsule and preparation method thereof |
| CN102771781A (en) * | 2011-05-07 | 2012-11-14 | 于文利 | Preparation method of novel nano DNA nutrition powder |
| CN102228257A (en) * | 2011-06-27 | 2011-11-02 | 湖北福星生物科技有限公司 | Algal oil DHA (Docosahexaenoic Acid) microcapsule and preparation method thereof |
| CN103549442A (en) * | 2013-11-01 | 2014-02-05 | 厦门汇盛生物有限公司 | High-oil-load DHA (docosahexaenoic acid) algae oil microcapsule powder and preparation technique thereof |
| CN104719510A (en) * | 2015-03-20 | 2015-06-24 | 湖南洋膳科技有限公司 | Pregnant woman and infant nutritional tea oil containing DHA and AA |
| CN105661545A (en) * | 2016-01-28 | 2016-06-15 | 武汉欧米嘉生物医药有限公司 | Alpha-linolenic acid microcapsule capable of being directly used for cooking and preparation method of alpha-linolenic acid microcapsule |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110692962A (en) * | 2019-10-12 | 2020-01-17 | 山东省食品发酵工业研究设计院 | Preparation method of winter jujube composite powder containing DHA algae oil nanoparticles |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107048405A (en) | Aliphatic acid component microcapsules and preparation method thereof | |
| CN101125133B (en) | Unsaturated fatty acid microcapsule preparing technology and application | |
| CN108430461B (en) | Preparation method of high-stability microcapsule dry powder/particles containing fat-soluble nutrients with more double bonds | |
| AU2020102945A4 (en) | Compound oil microcapsule with reasonable fatty acid proportion and high stability and its preparation method thereof | |
| CN104432059B (en) | A kind of anti-acid microalgae DHA grease microscapsule powder | |
| CN101259102B (en) | Micrometre level docosahexaenoic acid emulsion and preparation thereof | |
| CN104957622A (en) | Flax stabilizing emulsion and preparing method of flax stabilizing emulsion | |
| CN110742130A (en) | Infant formula goat milk powder added with liposome simulating breast milk fat structure and preparation method thereof | |
| CN105613789A (en) | High-fat and high-dietary-fiber composite animal and plant powdered oil and preparation method and application thereof | |
| CN107660620B (en) | Sheep-based oil microcapsule powder and preparation method thereof | |
| CN107136511A (en) | A kind of peony seed oil composition for promoting cranial nerve development, Peony-seed-oil soft capsule and preparation method thereof | |
| CN111685190A (en) | Nano-scale DHA algae oil powder and emulsification preparation method thereof | |
| CN106901373A (en) | Edible acer truncatum seed oil capsule of nano of a kind of health care for the middle and old aged and preparation method thereof | |
| CN107669657A (en) | A kind of preparation method high-stability microencapsulated containing more double bond fat soluble nutrient | |
| CN111053143A (en) | Green and healthy sandwich gel candy rich in nutrition and preparation method thereof | |
| CN111657497A (en) | Ketogenic diet for resisting food protein allergy and preparation method thereof | |
| TW201236578A (en) | Nutritional products comprising beta-hydroxy-beta-methylbutyrate | |
| CN105379843A (en) | Preparation method of milk powder containing multi-unsaturated fatty acid grease | |
| CN108142950A (en) | A kind of acer truncatum seed oil composite Nano microcapsule powder for improving brain neuroblastoma and preparation method thereof | |
| CN105326044A (en) | Composite fish oil microcapsule and preparation method thereof | |
| CN107467667B (en) | A kind of compound preparation contained there are two types of unrighted acid and sialic acid | |
| CN109123660A (en) | A kind of walnut lactalbumin composite powder and preparation method thereof for maternal nutritional product | |
| CN101167793A (en) | Walnut oil fat emulsion and manufacturing method thereof | |
| CN106666747A (en) | Water-soluble fatty acid component nano-particles for infants | |
| AU2014372631A1 (en) | Composition comprising ferric saccharate and high concentrations of microencapsulated LC-PUFA with a reduced off taste |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170517 |